Products Everolimus
Everolimus Phase 2 Completed ⚡ Active Pediatric Recurrent Progressive Low-grade Gliomas
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
Dec 13, 2012 → Jul 31, 2024
About Everolimus Everolimus is a phase 2 stage product being developed by Novartis for Pediatric Recurrent Progressive Low-grade Gliomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01734512. Target conditions include Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas.
Clinical Trials (20) NCT ID Phase Status Start Completion Indication NCT00655252 Pre-clinical Completed — — Metastatic Renal Cell Cancer NCT05108740 Pre-clinical Completed — — Advanced Hormone Receptor Positive (HR+) Breast Cancer NCT05252585 Approved Active May 1, 2023 Nov 25, 2026 Renal Angiomyolipoma NCT03525834 Approved Completed Nov 9, 2018 Sep 25, 2020 Renal Angiomyolipoma NCT02962414 Phase 3 Active Jun 8, 2017 Aug 13, 2027 Tuberous Sclerosis Complex NCT02842749 Approved Completed Mar 14, 2016 Feb 22, 2024 Pancreatic Neuroendocrine Tumors NCT02429869 Approved Completed Feb 24, 2016 Jan 31, 2018 HIV NCT02539459 Phase 2 Terminated Sep 23, 2015 Aug 20, 2018 Sporadic Angiomyolipomas (AMLs) NCT02687958 Phase 2 UNKNOWN May 1, 2015 Dec 1, 2023 Neuroendocrine Carcinoma NCT02376985 Phase 3 Completed Mar 26, 2015 Oct 16, 2018 Breast Cancer NCT02338609 Approved Completed Dec 17, 2014 Dec 18, 2023 Growth and Development NCT02236572 Phase 2 Terminated Nov 29, 2014 Mar 1, 2021 Breast Cancer NCT02273752 Phase 2 Terminated Nov 1, 2014 Dec 1, 2015 Estrogen Receptor-positive Breast Cancer NCT02201212 Phase 2 Completed Sep 1, 2014 Jun 1, 2019 TSC1 NCT01864070 Phase 1 Withdrawn May 1, 2014 — Liver Cancer NCT01997255 Phase 2 Withdrawn Apr 1, 2014 Apr 1, 2016 Sturge Weber Syndrome NCT02096107 Approved Completed Feb 1, 2014 May 1, 2017 Graft Dysfunction NCT02017860 Phase 2 Completed Jan 16, 2014 Apr 25, 2019 Neoplasms NCT01636466 Phase 3 Terminated Jun 1, 2013 May 1, 2014 Kidney Failure, Chronic NCT01609673 Pre-clinical Terminated Mar 1, 2013 May 1, 2013 End Stage Renal Failure With Renal Transplant
Competing Products 20 competing products in Pediatric Recurrent Progressive Low-grade Gliomas
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3
Other Products from Novartis